133 related articles for article (PubMed ID: 23412805)
1. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.
Simonsson M; Söderlind V; Henningson M; Hjertberg M; Rose C; Ingvar C; Jernström H
Cancer Causes Control; 2013 May; 24(5):929-40. PubMed ID: 23412805
[TBL] [Abstract][Full Text] [Related]
2. Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status.
Bågeman E; Ingvar C; Rose C; Jernström H
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):895-901. PubMed ID: 18398030
[TBL] [Abstract][Full Text] [Related]
3. Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels.
Klug TL; Bågeman E; Ingvar C; Rose C; Jernström H
Mol Genet Metab; 2006 Dec; 89(4):381-9. PubMed ID: 16978896
[TBL] [Abstract][Full Text] [Related]
4. Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer.
Rosendahl AH; Perks CM; Zeng L; Markkula A; Simonsson M; Rose C; Ingvar C; Holly JM; Jernström H
Clin Cancer Res; 2015 Apr; 21(8):1877-87. PubMed ID: 25691730
[TBL] [Abstract][Full Text] [Related]
5. High coffee intake, but not caffeine, is associated with reduced estrogen receptor negative and postmenopausal breast cancer risk with no effect modification by CYP1A2 genotype.
Lowcock EC; Cotterchio M; Anderson LN; Boucher BA; El-Sohemy A
Nutr Cancer; 2013; 65(3):398-409. PubMed ID: 23530639
[TBL] [Abstract][Full Text] [Related]
6. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
[TBL] [Abstract][Full Text] [Related]
7. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
Kotsopoulos J; Ghadirian P; El-Sohemy A; Lynch HT; Snyder C; Daly M; Domchek S; Randall S; Karlan B; Zhang P; Zhang S; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):912-6. PubMed ID: 17507615
[TBL] [Abstract][Full Text] [Related]
8. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
10. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
12. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.
Jernström H; Bågeman E; Rose C; Jönsson PE; Ingvar C
Br J Cancer; 2009 Dec; 101(11):1817-23. PubMed ID: 19935798
[TBL] [Abstract][Full Text] [Related]
13. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.
Khoshnoud MR; Löfdahl B; Fohlin H; Fornander T; Stål O; Skoog L; Bergh J; Nordenskjöld B
Breast Cancer Res Treat; 2011 Apr; 126(2):421-30. PubMed ID: 20957430
[TBL] [Abstract][Full Text] [Related]
15. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
16. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of breast cancer in relation to coffee, tea and caffeine in Sweden.
Oh JK; Sandin S; Ström P; Löf M; Adami HO; Weiderpass E
Int J Cancer; 2015 Oct; 137(8):1979-89. PubMed ID: 25885188
[TBL] [Abstract][Full Text] [Related]
19. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
20. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
